StockData

Rigel Pharmaceuticals vs UroGen Pharma

RIGL and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RIGL and URGN compare

UroGen Pharma is the larger company, worth 1.8 times as much as Rigel Pharmaceuticals ($1.5B against $802M).

UroGen Pharma grew revenue faster over the last twelve months (100% versus 3.3% for Rigel Pharmaceuticals).

Rigel Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 116% compared with −51.7% at UroGen Pharma.

Rigel Pharmaceuticals scores higher on the StockData Score (11 against 6 for UroGen Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRIGLURGN
Size and price
Market cap$802M$1.5B
Share price$42.92$29.87
Change, 1 year2.3%25.7%
Change, 5 years54.9%146%
Beta (5Y)2.152.73
Employees174291
StockData Score
Total score11 (better)6
Valuation score3 (better)0
Growth score13 (better)
Performance score4 (better)2
Health score3 (better)1
Dividend score00
Valuation
P/E2.7×–
P/S2.9× (better)7.7×
P/B1.9×–
EV/EBITDA7.9×–
FCF yield–−10.9%
Growth
Revenue growth (TTM)3.3%100% (better)
Revenue growth, 5Y average22.1%56.2% (better)
Net income growth (TTM)229%–
EPS growth (TTM)196%–
Profitability
Gross margin91.4% (better)90.8%
Operating margin31.5% (better)−35.3%
Net margin116% (better)−51.7%
FCF margin–−84.3%
Return on equity127%–
Return on invested capital57.4%–
Financial health
Interest coverage15.0×–
Current ratio1.943.80 (better)
Altman Z-score3.64 (better)−2.55
Piotroski F-score7 (better)0
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions87.7%86.8%
Held by insiders3.3%5.6%
Insider net buying, 12 months−$306K (better)−$4.5M
Short interest, % of float14.0%11.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.